Gateway Wealth Partners LLC Takes $545,000 Position in Bristol Myers Squibb Company $BMY

Gateway Wealth Partners LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,986 shares of the biopharmaceutical company’s stock, valued at approximately $545,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at $25,000. Physician Wealth Advisors Inc. lifted its position in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the period. Bayban purchased a new position in Bristol Myers Squibb during the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb in the 4th quarter worth about $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $64.98 on Friday. The stock’s 50-day moving average is $57.90 and its 200-day moving average is $58.29. The company has a market cap of $132.70 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $65.56.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Weiss Ratings cut Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported second-quarter adjusted EPS of $2.04, well above the $1.60 analyst consensus and up from $1.46 a year earlier. Revenue increased 5.7% year over year to $12.97 billion, exceeding estimates of approximately $11.74 billion. Bristol Myers raises 2026 forecast as Eliquis and newer medicines power results
• Positive Sentiment: The company raised its full-year 2026 outlook to EPS of $6.75-$7.00 and revenue of $49 billion-$50 billion, above consensus forecasts. Management cited strong performance from blood thinner Eliquis and newer products including Camzyos and Reblozyl. Bristol Myers Squibb raises 2026 revenue outlook
• Positive Sentiment: The growth portfolio reportedly expanded 14%, with continued momentum from Opdivo Qvantig, Breyanzi and Iza-bren. Strong cash flow and a valuation viewed as inexpensive relative to large pharmaceutical peers, along with a dividend yield near 4%, supported bullish analyst commentary. Bristol Myers Squibb upgraded to Buy on positive earnings and outlook
• Neutral Sentiment: Analysts noted that the transition away from older products remains incomplete. Opdivo sales declined, while patent expirations and legacy portfolio weakness continue to pressure revenue.
• Negative Sentiment: Delayed clinical readouts for Milvexian and Cobenfy, as well as mixed performance from certain pipeline assets, may limit near-term catalysts. Unusually heavy put-option activity also signals that some traders remain cautious about downside risks. Bristol Myers Squibb second-quarter earnings call highlights

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.